Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
4
80%
Ph phase_2
1
20%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

NCT00003086
completedphase_2

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

NCT00450619
completedphase_1

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00316940
completedphase_1

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

NCT00602706
completedphase_1

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00478075

Clinical Trials (5)

Showing 5 of 5 trials
NCT00003086Phase 1

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Terminated
NCT00450619Phase 2

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Completed
NCT00316940Phase 1

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00602706Phase 1

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Completed
NCT00478075Phase 1

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5